Research Article
Outcomes of Severe Sepsis and Septic Shock Patients on Chronic Antiplatelet Treatment: A Historical Cohort Study
| | | No antiplatelets
N = 379 | Antiplatelets
N = 272 | O.R. (95% CI)
| P value |
| | Hospital death n (%) | 98 (25.9) | 57 (21) | 0.76 (0.52–1.10) | 0.15 | | ICU death, n (%) | 46 (12.1) | 26 (9.6) | 0.77 (0.46–1.27) | 0.3 | | Hospital length of stay days, median (IQR) | 9.3 (5.5–16.9) | 8.9 (5.6–15.7) | | 0.86 | | ICU length of stay days, median (IQR) | 2.5 (1.3–5.8) | 2.3 (1.3–4.7) | | 0.31 | | ARDS/ALI, n (%) | 132 (34.8) | 57 (21) | 0.50 (0.35–0.71) | <0.001 | | Invasive mechanical ventilation, n (%) | 158 (41.7) | 84 (30.9) | 0.62 (0.45–0.87) | 0.005 | | Length of invasive mechanical ventilation days, median (IQR) | 3.3 (1.3–8) | 3.5 (1.8–7) | | 0.99 | | Noninvasive mechanical ventilation, n (%) | 68 (17.9) | 50 (18.4) | 1.03 (0.64–1.54) | 0.89 | | Length of noninvasive mechanical ventilation days, median (IQR) | 0.64 (0.2–1.8) | 1 (0.4–2) | | 0.18 | | Acute kidney injury, n (%) | 299 (78.9) | 218 (80.2) | 1.08 (0.73–1.59) | 0.70 | | Stage of acute kidney injury | | | | | | Stage 1, n (%) | 126 (33.3) | 102 (37.5) | | NS | | Stage 2, n (%) | 63 (16.6) | 44 (16.2) | | NS | | Stage 3, n (%) | 110 (29) | 72 (26.5) | | NS | | Renal replacement therapy, n (%) | 85 (22.4) | 53 (19.5) | 0.84 (0.57–1.23) | 0.37 | | Length of renal replacement therapy days, median (IQR) | 6 (3–11) | 4 (2–8) | | 0.22 |
|
|
n: number, %: percentage, IQR: interquartile range, ARDS/ALI: acute respiratory distress syndrome/acute lung injury.
|
